Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia.

abstract：OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

journal_title：Prostate cancer and prostatic diseases

authors： Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

更新日期：2018-09-01 00:00:00

abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...

journal_title：Prostate cancer and prostatic diseases

authors： Sedelaar JP,De La Rosette JJ,Beerlage HP,Wijkstra H,Debruyne FM,Aarnink RG

更新日期：1999-12-01 00:00:00

abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

journal_title：Prostate cancer and prostatic diseases

authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

更新日期：2010-06-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

更新日期：2007-01-01 00:00:00

abstract：:Epidemiological studies have suggested an association between low selenium levels and the development of prostate cancer. Human cellular glutathione peroxidase I (hGPX1) is a selenium-dependent enzyme that protects against oxidative damage and its peroxidase activity is a plausible mechanism for cancer prevention by s...

journal_title：Prostate cancer and prostatic diseases

authors： Kote-Jarai Z,Durocher F,Edwards SM,Hamoudi R,Jackson RA,Ardern-Jones A,Murkin A,Dearnaley DP,Kirby R,Houlston R,Easton DF,Eeles R,CRC\/BPG UK Familial Prostrate Cancer Collaborators.

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

journal_title：Prostate cancer and prostatic diseases

authors： Gökce MI,Sundi D,Schaeffer E,Pettaway C

更新日期：2017-06-01 00:00:00

abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Rossi PJ,Jani AB,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Accumulating evidence suggests that obesity is associated with tumor progression in prostate cancer (PCa) patients after radical prostatectomy (RP). We conducted a retrospective multicenter study to determine the effect of body mass index (BMI) on the clinicopathological characteristics and biochemical recur...

journal_title：Prostate cancer and prostatic diseases

authors： Narita S,Mitsuzuka K,Yoneyama T,Tsuchiya N,Koie T,Kakoi N,Kawamura S,Kaiho Y,Ohyama C,Tochigi T,Yamaguchi T,Habuchi T,Arai Y

更新日期：2013-09-01 00:00:00

abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...

journal_title：Prostate cancer and prostatic diseases

authors： Galvão DA,Taaffe DR,Spry N,Newton RU

更新日期：2007-01-01 00:00:00

abstract：:This session included five presentations in the areas of pathology of precursor lesions and carcinoma of the prostate, the value of determining neovascularity in the diagnosis and staging of prostate cancer, new 'molecular' markers, correlation between pre- and postoperative Gleason scores and a study dealing with tra...

journal_title：Prostate cancer and prostatic diseases

authors： Sakr WA,Brawer MK,Moul JW,Donohue R,Schulman CG,Sakr D

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...

journal_title：Prostate cancer and prostatic diseases

authors： Howard LE,Zhang J,Fishbane N,Hoedt AM,Klaassen Z,Spratt DE,Vidal AC,Lin D,Hitchins MP,You S,Freeman MR,Yamoah K,Davicioni E,Freedland SJ

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (RT). METHODS:This was a phase 2 single-arm prospective open...

journal_title：Prostate cancer and prostatic diseases

authors： Armstrong AJ,Halabi S,Healy P,Lee WR,Koontz BF,Moul JW,Mundy K,Creel P,Wood S,Davis K,Carducci MA,Stein M,Hobbs C,Reimer B,Nguyen M,Anand M,Bratt L,Kim S,Tran PT,George DJ,Department of Defense Prostate Cancer Cli

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...

journal_title：Prostate cancer and prostatic diseases

authors： Zaidi S,Gandhi J,Joshi G,Smith NL,Khan SA

更新日期：2019-09-01 00:00:00

abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

journal_title：Prostate cancer and prostatic diseases

authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...

journal_title：Prostate cancer and prostatic diseases

authors： Wadhwa H,Terris MK,Aronson WJ,Kane CJ,Amling CL,Cooperberg MR,Freedland SJ,Abern MR

更新日期：2016-12-01 00:00:00

abstract：:An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe w...

journal_title：Prostate cancer and prostatic diseases

authors： Ross AE,D'Amico AV,Freedland SJ

更新日期：2016-03-01 00:00:00

abstract：:We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

journal_title：Prostate cancer and prostatic diseases

authors： Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

更新日期：2008-01-01 00:00:00

abstract：:New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

journal_title：Prostate cancer and prostatic diseases

authors： Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...

journal_title：Prostate cancer and prostatic diseases

authors： Blackwell JEM,Doleman B,Boereboom CL,Morton A,Williams S,Atherton P,Smith K,Williams JP,Phillips BE,Lund JN

更新日期：2020-12-01 00:00:00

abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...

journal_title：Prostate cancer and prostatic diseases

authors： Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C

更新日期：2000-11-01 00:00:00

abstract：BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...

journal_title：Prostate cancer and prostatic diseases

authors： McGregor B,Zhang L,Gray KP,Shaw G,Evan C,Francini E,Sweeney C

更新日期：2020-09-03 00:00:00

abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...

journal_title：Prostate cancer and prostatic diseases

authors： Diss JK,Stewart D,Pani F,Foster CS,Walker MM,Patel A,Djamgoz MB

更新日期：2005-01-01 00:00:00

abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...

journal_title：Prostate cancer and prostatic diseases

authors： Hammarsten J,Högstedt B,Holthuis N,Mellström D

更新日期：1998-03-01 00:00:00

abstract：PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

journal_title：Prostate cancer and prostatic diseases

authors： Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

更新日期：2003-01-01 00:00:00

abstract：:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...

journal_title：Prostate cancer and prostatic diseases

authors： Zhou T,Xu C,He M,Sun Y

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...

journal_title：Prostate cancer and prostatic diseases

authors： Tosco L,Laenen A,Briganti A,Gontero P,Karnes RJ,Albersen M,Bastian PJ,Chlosta P,Claessens F,Chun FK,Everaerts W,Gratzke C,Graefen M,Kneitz B,Marchioro G,Salas RS,Tombal B,Van den Broeck T,Moris L,Battaglia A,van d

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

journal_title：Prostate cancer and prostatic diseases

authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

更新日期：2019-03-01 00:00:00

abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

journal_title：Prostate cancer and prostatic diseases

authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

journal_title：Prostate cancer and prostatic diseases

authors： Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

更新日期：2014-09-01 00:00:00